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Objective. Transforming growth factor b1 (TGFb1) is considered a key factor in fibrogenesis, and blocking TGFb1 signaling pathways diminishes fibrogenesis in animal models. The objective of this study was to determine whether nelfinavir mesylate (NFV), a drug approved by the Food and Drug Administration (FDA) for treating HIV infection, could be repurposed to treat pulmonary fibrosis in patients with systemic sclerosis (SSc).
Methods. Normal human lung, ventricular, and skin fibroblasts as well as lung fibroblasts from SSc patients were used to determine the effects of NFV on fibroblast-to-myofibroblast differentiation mediated by TGFb1. The efficacy of NFV was also evaluated in an animal model of SSc (bleomycin-induced pulmonary fibrosis). In addition, in silico analysis was performed to determine novel off-target effects of NFV.
Results. NFV inhibited TGFb1-mediated fibroblast-to-myofibroblast differentiation in lung fibroblasts through inhibition of the TGFb1 canonical pathway. NFV also inhibited differentiation of skin and ventricular fibroblasts and adipocyte precursors into myofibroblasts. Activation of the TGFb1/mechanistic target of rapamycin pathway inhibited autophagy in lung fibroblasts, favoring collagen deposition, and NFV counteracted this effect in a dose-dependent manner. Moreover, NFV significantly reduced lung injury and collagen deposition in an animal model of SSc. In silico analysis of NFV binding proteins revealed new putative beneficial mechanisms of action, consistent with known common pathways in fibrogenesis.
Conclusion. NFV abrogates TGFb1-mediated fibroblast-to-myofibroblast differentiation and pulmonary fibrosis through off-target protein binding, a finding that supports consideration of this FDA-approved medication as an antifibrotic agent.
There are currently~75,000 people diagnosed as having systemic sclerosis (SSc; scleroderma) in the US. This disease most commonly presents in women ages 30-50 years and carries a high mortality rate (1) . SScassociated interstitial lung disease (ILD) affects 40% of patients with SSc and portends a worse prognosis, with a 9-year survival rate of~30%, as opposed to almost 72% when ILD is not detected (2) .
The pathogenesis of lung fibrosis associated with SSc remains incompletely understood. Transforming growth factor b1 (TGFb1) is recognized as a key factor in the pathogenesis of SSc, as it induces differentiation of fibroblasts into myofibroblasts and fosters collagen deposition. Indeed, scleroderma biopsy samples show activation of the TGFb1 signaling pathway, which leads to excessive accumulation of extracellular matrix (ECM) (3, 4) . There is a dire need for new therapeutic approaches, especially because the perceived pulmonary benefits of currently used antiinflammatory therapies are only modest, and the therapies themselves manifest significant long-term toxicities.
Nelfinavir (NFV) was approved by the Food and Drug Administration (FDA) in 1997 and has been used in combination with reverse transcriptase inhibitors for the treatment of HIV type 1 (HIV-1) infection (1) . Mechanistically, NFV inhibits HIV-1 and HIV-2 proteases, which are critical for HIV replication (2) . However, HIV is not the only therapeutic target of this drug, as several clinical trials are underway to investigate the efficacy of NFV in treating various cancers (3, 4) . NFV induces autophagy and inhibits cancer cell proliferation (5) . More recently, NFV has been demonstrated to reduce inflammation through activation of protein phosphatase 2 (PP-2) and inhibition of MAPK signaling in macrophages (6) .
The reported features of NFV, when extrapolated to the biology of pulmonary fibrosis, suggest that this drug may be a good candidate for treating recalcitrant fibrotic lung diseases. NFV is metabolized by the cytochrome P450 system, which accounts for its half-life of~5 hours (7) . The safety of long-term NFV ingestion for treating HIV is well established, making this agent a suitable candidate for drug repositioning. Our present study demonstrates that NFV reduces the expression of collagen, fibronectin, and a-smooth muscle actin (a-SMA) that occurs in response to TGFb1 in normal and SSc fibroblasts. This occurs through deregulation of Smad2/3 activation and the Akt/mechanistic target of rapamycin (mTOR) pathway, as well as via induction of autophagy. Use of NFV in an SSc animal model reduces the extent of lung lesions and collagen deposition. Thus, we propose clinical trials using NFV for the treatment of SSc because of its off-target inhibitory effects on fibrogenic pathways.
MATERIALS AND METHODS
Cell cultures. Normal human lung fibroblasts (HLFs), primary adult skin fibroblasts, and human cardiac ventricular fibroblasts were purchased from Lonza (catalog nos. CC-2512, CC-2511, and CC-2904) and cultured following the manufacturer's instructions. Normal HLFs were placed in low-serum media for 24 hours before adding NFV in low-serum media (fibroblast basal medium 2 with 0.2% bovine serum albumin). NFV mesylate hydrate was purchased from Sigma-Aldrich (catalog no. PZ0013), and a stock solution was prepared following the manufacturer's instructions. After serum starvation, normal HLFs were pretreated for 24 hours with NFV (0-21 lM) or API-2 (Tocris) before adding TGFb1 (R&D Systems).
Lung fibroblasts isolated from SSc patients (n = 4) and controls (n = 4) were provided by the National Scleroderma Core Center at the Medical University of South Carolina. Human subcutaneous tissue stem cells (adipose-derived mesenchymal stem cells) were purchased from Lonza (catalog no. PT-5006) and were differentiated following the manufacturer's instructions using adipocyte differentiation medium (preadipocyte basal medium-2/preadipocyte differentiation medium; Lonza) for 10 days. Cells displaying characteristic adipocyte morphology by phase-contrast microscopy were pretreated with 12 lM NFV or vehicle and incubated in media with 3 ng/ml of human recombinant TGFb1 for up to 72 hours. Experiments were performed in triplicate and repeated at least 3 times.
Gel contraction assay. Gel contraction assays were performed using 12-well plastic culture plates (Corning). Rat tail type I collagen (BD Biosciences) was used to construct the 3-dimensional gel. The assay protocol we used has been previously described (8) .
Immunoprecipitation and liquid chromatography mass spectrometry (LC-MS) analysis. Total extracts from normal HLFs were immunoprecipitated with an antibody against type I collagen a1 chain (1:5,000 dilution; Abcam) and visualized on a 4-12% polyacrylamide gel. After Coomassie blue staining, the band was dissected for LC-MS analysis. Further details are available upon request from the corresponding author.
Animal model of SSc. Mice were obtained from The Jackson Laboratory. Male C57BL/6 mice ages 6-8 weeks were pretreated for 3 days with daily subcutaneous injections of 2.5 mg NFV or vehicle. From day 4 onward, the mice (6-7 per group) received daily subcutaneous injections of bleomycin (Teva Parenteral Medicines) at 4,800 mU/kg in phosphate buffered saline (PBS) or vehicle control (PBS alone). Body weight was recorded daily. On day 31, all mice were killed, and lung tissue was analyzed histologically with both hematoxylin and eosin (H&E) and Masson's trichrome staining. Expression of markers of fibrosis was analyzed by quantitative reverse transcription-polymerase chain reaction (qRT-PCR) and Western blotting. Details are available upon request from the corresponding author.
Electron microscopy. Confirmatory transmission electron microscopy and quantitative autophagosome analysis were performed as described previously (9) .
In silico proteome-wide screening. The in silico proteome-wide docking analysis was performed using PROBEx from the Ligand Express computational suite (Cyclica) as described previously (10) . Briefly, the molecular structure of NFV (PubChem compound identifier [CID] : 64143) was screened for complementarity against a library of 240,971 protein surfaces, representing 80,923 publicly available macromolecular structures (11) . In total, the library of surfaces represents 29,581 unique UniProt accessions, of which 4,541 correspond to human proteins. HIV-1 protease (Gag-Pol; UniProt ID no. P03367; Protein Data Bank ID no. 2PYM), a known and negatively regulated target of NFV, was used as a positive control to benchmark calculated docking scores. A modified Z score and corresponding P values were calculated using a median-based method robust to dataset outliers.
Systems biology mapping of the predicted drug-protein interactome. The interconnectivity between NFV and statistically significant proteins identified from the in silico proteome-wide screen was analyzed using DIVEx from Ligand Express (10) . DisGeNET (12) , an open-source platform integrating gene-disease associations from the scientific literature and databases (i.e., UniProt, ClinVar, Orphanet, GWAS Catalog, Comparative Toxicogenomics Database; 429,036 associations between 17,381 genes and 15,093 diseases, disorders, and clinical or abnormal human phenotypes), was used to enrich for targets associated with SSc (Unified Medical Language System [UMLS]: C0036421), pulmonary fibrosis (UMLS: C0034069), and/or idiopathic pulmonary fibrosis (UMLS: C1800706).
Modulator effect predictions. Modulatory effects of significant NFV-protein interactions identified by the in silico proteome-wide screen were predicted using SWITCHx from Ligand Express (10) (further information is available upon request from the corresponding author).
Statistical analysis. All data are expressed as the mean AE SEM. Comparisons between 2 groups were performed using Student's unpaired 2-tailed t-tests. Analysis of variance and Bonferroni's multiple comparison tests were used for multiple 116 SANCHEZ ET AL groups. P values less than 0.05 were considered significant. All experiments were performed at least 3 times. A more detailed description of the methods is available upon request from the corresponding author.
RESULTS
NFV inhibits myofibroblast differentiation from normal lung, skin, and heart fibroblasts as well as from lung fibroblasts of patients with SSc. To identify the effects of NFV on fibroblast-to-myofibroblast differentiation, lung fibroblasts from 4 controls and 4 SSc patients as well as commercially available normal HLFs, primary adult skin fibroblasts, and human cardiac ventricular fibroblasts were pretreated with NFV for 24 hours before exposure to TGFb1 (1 ng/ml) for 24 hours. Changes in gene expression for markers of fibrosis were assessed by Western blotting and qRT-PCR. The results were consistent across multiple experiments (n = 3). NFV significantly reduced the expression of fibroblast-to-myofibroblast differentiation markers, including type I collagen, a-SMA, and plasminogen activator inhibitor 1 (PAI-1), in lung fibroblasts pretreated with NFV ( Figures 1A and B) . Akt phosphorylation mediated by TGFb1 was also impaired by NFV ( Figure 1A ). Furthermore, NFV down- Figure 1 . Nelfinavir mesylate (NFV) inhibits markers of myofibroblast differentiation in fibroblasts derived from multiple tissue origins. Normal human lung fibroblasts (NHLF), lung fibroblasts (obtained from the National Scleroderma Core Center) from 4 different systemic sclerosis (SSc) patients (e.g., SSc1 and SSc2) and 4 controls (nonfibrotic lung fibroblasts [NLF]) (e.g., NL1 and NL2), commercial normal dermal fibroblasts (NHDF), and commercial cardiac ventricular fibroblasts (NHVF) were pretreated for 24 hours with NFV or vehicle and then treated for 24 hours with 1 ng/ml of transforming growth factor b1 (TGFb1). A, Western blot analysis of total and phosphorylated protein kinase B (Akt), type I collagen, and a-smooth muscle actin (a-SMA), assessed from whole cell extracts. B, Densitometry of the Western blots for type I collagen. Values are the mean AE SEM. C, Western blot analysis of total extracts from control (Cont) normal human lung fibroblasts, normal human lung fibroblasts pretreated with NFV, and normal human lung fibroblasts pretreated for 24 hours with an Akt inhibitor (API-2) before treatment with TGFb1 for an additional 24 hours. D, Collagen contraction assay of normal human lung fibroblasts pretreated with 12 lM NFV, showing the percentage of matrix contraction compared to control. Symbols represent individual samples; bars show the mean AE SEM. Representative images from the collagen contraction assay are shown. In B, *** = P < 0.001 versus treatment with TGFb1 alone. In C, * = P < 0.01 versus NFV. In D, * = P < 0.05; ** = P < 0.005; *** = P < 0.001. FN = fibronectin; PAI-1 = plasminogen activator inhibitor 1; NT = not treated. regulated the expression of type I collagen in primary adult skin fibroblasts, human cardiac ventricular fibroblasts, SSc lung fibroblasts, and normal HLFs treated with TGFb1 ( Figure 1B ). NFV also reduced the expression of fibrotic markers in a dose-dependent manner, with the maximal effects observed at 12 lM (further information is available upon request from the corresponding author).
To determine whether NFV-mediated decrease in Akt phosphorylation alone was sufficient to inhibit fibroblast-to-myofibroblast differentiation, fibroblasts were treated with TGFb1 and an Akt inhibitor, API-2 (13) ( Figure 1C ). API-2 decreased Akt phosphorylation compared to NFV, but it did not completely inhibit a-SMA expression. These results suggest that NFV acts by other mechanisms in addition to Akt inhibition.
A type I collagen matrix contraction assay was used to evaluate myofibroblast contractile function. Contraction by normal HLFs treated with TGFb1 in the presence of NFV (12 lM) was significantly less than contraction by fibroblasts treated with TGFb1 alone ( Figure 1D ). Western blot analysis of fibroblasts isolated from the contraction assay gels confirmed a significant decrease in a-SMA expression in response to NFV (further information is available upon request from the corresponding author). Taken together, our results show that NFV inhibits type I collagen matrix contraction in lung fibroblasts treated with TGFb1 by inhibiting fibroblast-to-myofibroblast differentiation.
NFV cannot rescue adipocyte-myofibroblast differentiation. Adipose tissue loss and adipocyte-myofibroblast transition were recently identified as 2 of the primary events in the pathogenesis of cutaneous fibrosis that represent novel potential targets for therapeutic intervention for SSc (14) . To test the effect of NFV (12 lM) on adipocyte loss and myofibroblast transdifferentiation from adipocyte-derived cells, human adipose tissue-derived progenitor cells were incubated in differentiation media for 10 days until they acquired adipocyte morphology.
On brightfield examination, adipocytes were characterized by their round shape and prominent intracytoplasmic lipid accumulation, confirmed by oil red staining and expression of perilipin 1 and adiponectin (Figure 2A) . Following TGFb1 treatment for 24 hours, adipocytes exhibited reduced lipid content and reduced expression of perilipin 1, while increased expression of a-SMA and other myofibroblast markers, such as fibronectin EDA, was observed. The results indicate that cotreatment with 12 lM NFV cannot rescue TGFb1-mediated adipocyte differentiation as measured by bright light imaging (results not shown) and oil red staining (Figure 2A ). Coimmunofluorescence analysis confirmed that TGFb1 induced a progressive loss of adipocyte markers with acquisition of myofibroblast markers. Although we found that NFV could not completely prevent the effects of TGFb1 in this cellular system (Figure 2A) , Western blot analysis of cell extracts from adipocytes treated with TGFb1 alone or in combination with NFV indicated that NFV reduced the expression of a-SMA but could not maintain expression of perilipin 1 upon TGFb1 treatment ( Figures 2B and C) . Thus, TGFb1 promotes the progressive loss of adipocyte markers, accompanied by accumulation of the expression of a-SMA-positive stress fibers characteristic of myofibroblast differentiation from adipocytes, and cotreatment with NFV attenuates some myofibroblast features in this cellular system but cannot prevent the loss of the adipocyte phenotype.
NFV preconditioning inhibits activation of canonical TGFb1 signaling. To elucidate the molecular mechanisms involved in NFV-mediated inhibition of myofibroblast differentiation, the TGFb1 canonical and noncanonical pathways were studied. Canonical TGFb1 signaling involves activation of TGFb receptors and the downstream signal transducers Smad2 and Smad3. Normal HLFs were treated with TGFb1 after a 24-hour pretreatment with NFV, and then total cell extracts were collected at several time points for Western blot analysis of Smad2/3 expression and phosphorylation (an indicator of activation). Western blots showed that TGFb1 treatment induced Smad2/3 phosphorylation, and pretreatment with NFV protected the fibroblasts from TGFb1-induced Smad2/3 phosphorylation ( Figure 3A) . We noticed that total Smad3 levels were also decreased. Using Western blotting, we evaluated the impact of NFV on lung fibroblasts isolated from 4 controls and 4 SSc patients. The results confirmed that NFV inhibits Smad3 phosphorylation mediated by TGFb1 ( Figure 3B ). 
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As Smad3 can be dephosphorylated by PP-2A, we investigated whether the effects of NFV on Smad2/3 phosphorylation were PP-2A dependent by treating lung fibroblasts with okadaic acid, a PP-2 inhibitor, in the presence of NFV. Okadaic acid did not re-establish Smad3 phosphorylation ( Figure 3C ). We observed dose-dependent inhibition of the expression of PAI-1, a factor that is up-regulated by the canonical TGFb1 pathway, in response to NFV ( Figure 3D ). Taken together, these data demonstrate that NFV inhibits the TGFb1 canonical pathway independently of PP-2A activity.
NFV increases autophagic degradation of type I collagen and reduces contractibility during fibroblast-tomyofibroblast differentiation and in established myofibroblasts. NFV inhibits mTOR and induces autophagy in some cancer cells (15) . To determine the effect of NFV on lung fibroblasts, normal HLFs were pretreated with NFV (12 lM) for 24 hours before exposure to 1 ng/ml TGFb1. Western blot analysis of downstream targets of mTOR, a major regulator of autophagy, indicated that NFV inhibited activation of the mTOR pathway, as assessed by inhibition of ribosomal protein S6 kinase 1 phosphorylation. To assess the effects of NFV on autophagy, microtubuleassociated protein 1 light chain 3 (LC3) conversion (from LC3-I to LC3-II), which correlates with the number of autophagosomes, was evaluated by immunoblot analysis. In control fibroblasts, treatment with TGFb1 for 24 hours inhibited LC3B-I cleavage. The results demonstrated that NFV overcame deficient autophagy during fibroblast-tomyofibroblast differentiation in a dose-dependent manner ( Figure 4A ). We confirmed that NFV induced autophagy in normal HLFs using immunofluorescence for LC3B punctae and electron microscopy for identification of autophagolysosomes ( Figure 4B) .
To evaluate the effects of NFV in established lung fibrosis and the potential benefits of inducing autophagy in myofibroblasts, normal HLFs were treated for 48 hours with 1 ng/ml TGFb1 to stimulate their differentiation into myofibroblasts. The effects of NFV on type I collagen expression were measured after an additional 24 hours of TGFb1 treatment. Autophagic flux analysis of type I collagen was performed after 4 hours of treatment with bafilomycin A1 (100-400 nM) or vehicle in the presence or absence of NFV. Accordingly, normal HLFs were treated with bafilomycin A1, a potent and specific inhibitor of vacuolar H+ ATPase that prevents autophagic degradation of proteins (9) . Expression of type I collagen a1 chain and a-SMA were assessed by Western blot analysis.
Bafilomycin A1 (400 nM) inhibited type I collagen degradation by autophagolysosomes, resulting in re-establishment of type I collagen content in myofibroblasts treated with NFV ( Figure 4C ) (further information is available upon request from the corresponding author). These results indicate that NFV promoted targeting of type I collagen for autophagy in myofibroblasts. Conversely, a-SMA was not targeted for autophagic degradation and its expression did not change. We also determined the effect of NFV after the establishment of the myofibroblast phenotype in collagen gels. The results confirmed that NFV reduced myofibroblast contractibility after TGFb1 treatment (further information is available upon request from the corresponding author), but to a lesser extent than in normal lung fibroblasts (Figure 1 ). An MTT assay demonstrated no significant differences in cell survival with NFV concentrations up to 12 lM (further information is available upon request from the corresponding author).
Western blot analysis of myofibroblasts treated with NFV demonstrated a fragment of~70 kd, which was recognized by the anti-type I collagen antibody (Figure 4C ). This antibody recognizes both a1 and a2 chains of type I collagen, which have molecular weights of~180 kd and~150 kd, respectively. The 70-kd band was detected only in cytoplasmic extracts from NFV-treated myofibroblasts. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis of proteins immunoprecipitated with the antibody to type I collagen a1 chain revealed the same band in response to NFV treatment (further information is available upon request from the corresponding author). The band was excised and analyzed by MS using an ESI-TRAP instrument. Mascot search analysis revealed that the band represented the type I collagen a2 chain, with a score of 276 and 6 queries matches; this reached statistical significance (P < 0.001) (further information is available upon request from the corresponding author). The results support the hypothesis of the targeting of collagen through autophagy in NFV-treated fibroblasts.
Finally, we examined whether autophagy is induced in the lungs of mice chronically exposed to NFV via subcutaneous administration. For this purpose, 5 male mice per group were exposed via subcutaneous administration of NFV or vehicle for 28 days. The lungs were analyzed by immunohistochemistry with antibody to LC3B. LC3-positive cells were mostly detected in bronchiolar epithelial cells, alveolar cells, and areas of fibrotic lesion in bleomycin-treated lungs. The immunohistochemical analysis indicated that treatment with NFV resulted in an increase in LC3B staining, supporting the hypothesis of induction of autophagy ( Figure 4D) .
In silico analysis of NFV off-target effects supports its repurposing against fibrogenesis. Our data reveal that NFV inhibited TGFb1-mediated phosphorylation of Smad2 and Smad3 as well as noncanonical pathways including Akt/mTOR and p38 MAPK pathways (further information is available upon request from the corresponding author). 120 SANCHEZ ET AL NFV also acts as a proteasome inhibitor in some cancer cells (16) . Normal HLFs were pretreated with control media, NFV, or a reference proteasome inhibitor, bortezomib. Cell extracts were analyzed by Western blotting after 12 and 24 hours of NFV exposure for the accumulation of ubiquitinated proteins. After both pretreatment durations, compared to bortezomib, NFV (12 lM) failed to produce accumulation of ubiquitinated proteins (further information is available upon request from the corresponding author). In similar experiments with epithelial cells, NFV 
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induced marked accumulation of ubiquitinated proteins indicative of proteasome inhibition in lung cancer epithelial (A549) cells (further information is available upon request from the corresponding author). The results suggest that the effect of NFV is cell type specific, and the inhibitory effect of NFV on fibroblast-to-myofibroblast differentiation is independent of its proteasome activity.
To better understand the effect of NFV, we used an in silico proteome-wide screening to identify several off-target interactions that had docking scores comparable to those of the on-target interaction with HIV-1 protease. Overall, 6 predicted targets were identified following the examination of docking scores and known disease and pathway associations with their predicted modulatory 
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SANCHEZ ET AL effects; these included ribosomal S6 kinase A3 (RPS6KA3), phosphodiesterase 6C (PDE6C), epidermal growth factor receptor (EGFR), TGFb receptor type I (TGFbRI), TGFb-activated kinase 1 (TAB1), and focal adhesion kinase 1 (PTK2) (further information is available upon request from the corresponding author). However, since most of these targets had a stronger linkage with non-SSc disorders (i.e., RPS6KA3 with psychiatric disorders, PDE6C with ocular diseases, EGFR and PTK2 with various cancers) or had a weak linkage with SSc (i.e., TAB1) based on DisGeNET scores (12), TGFbRI was identified as a higher-ranking candidate. Further, docking scores of these predicted protein targets were then compared with those of 200 randomly selected proteins to provide a statistical validation of ligand-receptor suitability, and TGFbRI was among the top-scoring predictions (P = 0.006696), yielding scores comparable to those of HIV-1 protease (docking score -9.00, docking Z score -2.59; P = 0.004861) ( Figure 5A ) (further information is available upon request from the corresponding author).
We then constructed a classification model for TGFbRI, which forms clusters of known modulators of TGFbRI that are structurally similar and have the same modulatory effects on the protein, in order to predict the effect of NFV on TGFbRI ( Figure 5B ). Accordingly, 4 inhibitors of TGFbRI (PubChem CIDs: 44521016, 72375218, 44259, and 126565) were determined to be chemically similar to NFV ( Figure 5C ). Upon further inspection of the predicted binding site, NFV was found to colocalize with a known inhibitor of TGFbRI ( Figure 5D ). Taken together, these data suggest that NFV may inhibit TGFbRI as a putative mechanism of action in support of our in vitro results.
Interestingly, in silico proteome-wide screening suggested that NFV inhibits EGFR and PDE6C, both of which have known roles in the pathogenesis of pulmonary fibrosis (further information is available upon request from the corresponding author). In addition, NFV was predicted to inhibit RPS6KA3, a member of the family of p90 ribosomal S6 kinases that participate in pathologic remodeling of the heart (17), as well as PTK2, a non-receptor tyrosine kinase that plays an essential role in regulating cell migration, spreading, and reorganization, and in regulating the actin cytoskeleton. PTK2 inhibitors have demonstrated the potential to regulate pulmonary fibrosis in animal models and thus may be therapeutically relevant (18, 19) (further information is available upon request from the corresponding author). Overall, in silico analysis of the predicted human proteome-binding profile of NFV suggests that this small molecule may serve as a candidate for the treatment of pulmonary fibrosis associated with SSc.
NFV reduces lung fibrogenesis in an animal model of SSc. An animal model of SSc was used to evaluate the therapeutic effectiveness of NFV in pulmonary fibrosis. Six C57BL/6 male mice were exposed for 30 days to subcutaneous bleomycin or vehicle following pretreatment for 3 days with NFV. Histopathologic analysis using H&E (not shown) and Masson's trichrome staining revealed a significantly reduced percentage of lesions and collagen deposition in the lungs of mice treated with NFV compared to those treated with vehicle ( Figures 6A [left] and B). We analyzed the expression of CCN2, also known as connective tissue growth factor (CTGF), which may play an important role in lung fibrosis and repair of tissue including the dermis and lungs. Representative images of immunohistochemical staining for CCN2/CTGF are presented in Figure 6A (further information is available upon request from the corresponding author). The results confirm the reduction of CCN2/CTGF expression in accordance with the reduction in fibrosis. Furthermore, qRT-PCR of whole lung homogenates revealed decreased expression of messenger RNA for type I collagen and Hsp47 ( Figure 6C ). Taken together, the results indicate that NFV reduces lung fibrogenesis in an animal model of SSc.
DISCUSSION
Investigating new uses for safe and approved therapeutic drugs to treat chronic fibrotic diseases such as SSc is an option to consider, especially since the average time from target discovery to approval of a new drug is more than 13 years and the failure rate exceeds 95%. In the current study, we evaluated NFV, an FDA-approved HIV protease inhibitor, as a drug that might be repurposed for the treatment of SSc.
Excessive TGFb1 activity is an integral aspect of fibrogenesis. The profibrotic effects of TGFb1 are predominantly mediated by Smad3 signaling (20) . TGFb1/ Smad3 signaling promotes the myofibroblast phenotype through epithelial-mesenchymal transition and fibroblast-to-myofibroblast differentiation, key events in lung fibrogenesis (21) . Myofibroblasts are cells characterized by resistance to apoptosis, high expression of a-SMA, and the ability to contract and form collagen-rich ECM. In the present study, we demonstrated that NFV has a major impact on the prevention of myofibroblast differentiation from several tissue origins but preferentially from lung fibroblasts. Genetic approaches demonstrated that inhibition of the TGFb1/Smad3 signaling pathway prevents fibroblast-to-myofibroblast differentiation and experimental lung fibrosis (22) (23) (24) . We demonstrated that preconditioning with NFV in human lung fibroblasts attenuates Smad3 expression and Smad2/3 phosphorylation, leading to nuclear translocation and transcriptional activation of genes involved in fibrogenesis. During fibroblast-to-myofibroblast differentiation, TGFb1 also triggers several signaling pathways known as noncanonical pathways (25) , including phosphatidylinositol 3-kinase (PI3K)/Akt pathways (25) (26) (27) . NFV inhibits PI3K/Akt activation (5, 16, 28) . Akt activation enables multiple processes, such as proliferation, inflammation, survival, and glucose metabolism. Our findings, together with those reported in the literature, suggest that more than 1 mechanism may contribute to the antifibrotic effects of NFV in the animal model of scleroderma.
NFV is also a proteasome inhibitor (29) , and the ubiquitin-proteasome system has been shown to play a critical role in the regulation of proteins that affect inflammatory processes, cell growth, and cell differentiation (30) . Inhibiting proteasome activity prevents substrate degradation, which leads to modulation of proteins involved in the TGFb1 pathway and fibrogenesis (31) (32) (33) (34) . We demonstrated that NFV exerts strong proteasome inhibitor activity in alveolar epithelial cells, but its effect on TGFb1 signaling in human lung fibroblasts appeared to be independent of its proteasome activity at the concentrations evaluated (30) . Nevertheless, we demonstrated that NFV promotes autophagy in lung tissue and lung fibroblasts, which could be crucial to maintaining the fibroblast phenotype over the more fibrogenic myofibroblast. Our previous studies support the hypothesis that promotion of autophagy occurs in the lung in response to lung injury, but with chronological aging, our mechanisms of responding through autophagy diminish and thus exacerbate fibrogenesis (9) . Previous studies demonstrated that NFV induces autophagy in other cell types via mTOR pathway inhibition (35) . Indeed, autophagy is a key mechanism induced in response to cellular stress, survival, remodeling, tissue differentiation, and senescence (36) (37) (38) . We previously reported that TGFb1 inhibits autophagy through mTOR pathway activation (9) . However, other mechanisms may also contribute to reduced autophagy in pulmonary fibrosis and fibroblast-to-myofibroblast differentiation. One mechanism involves TGFb1-mediated effects on phosphorylated p38, which can potentially inhibit autophagy through phosphorylation of autophagy protein 5 at threonine 75, connecting autophagy and differentiation (39) . NFV inhibits p38 MAPK, which can promote autophagy during preconditioned tissue protection (40, 41) .
Our experiments show that NFV increased the rate of type I collagen degradation in established myofibroblasts, while inhibition of lysosome-autophagosome fusion increased type I collagen content. Interestingly, more pronounced collagen breakdown has been reported in fasting mice, potentially to provide salvage metabolites, amino acids, and other nutrients to the cells. However, it is unknown whether the rate of degradation of intracellular procollagens or extracellular mature collagens changes during lung aging and disease and whether this is linked to deficient autophagy (42) . We suggest that in vivo models for the study of cell type-dependent autophagy should be developed to evaluate normal and pathologic autophagy during lung injury, ensuing fibrogenesis, and fibrosis resolution.
In addition to the demonstrated effects of NFV, in silico analysis predicted several off-target and potentially beneficial consequences of NFV as an antifibrotic agent, including the negative modulation of TGFbRI, TAB1, RPS6KA3, PDE6C, EGFR, and PTK2. We confirmed that NFV inhibits phosphorylation of p38 MAPK activation and matrix contraction, which could be attributed to inhibition of TAB1 and/or PTK2 activity (18, 19, 43, 44) . Finally, we demonstrated the efficacy of NFV in preventing the development of pulmonary fibrosis in an animal model of SSc and in reducing the aberrant expression of CCN2/CTGF in the fibrotic tissue. More studies are needed to determine whether oral administration of NFV has similar antifibrotic results and to confirm the off-target mechanisms.
This study was fibroblast centric, and future studies are needed to determine the effect of NFV on airway epithelia, endothelium, and immune cells, considering their relevance to the pathophysiology of SSc. The effect of NFV on vessel medial wall thickness could not be addressed in this study, as our experimental approach did not lead to significant quantitative differences in vessel thickness between sham-and bleomycin-exposed mice (results not shown). Nevertheless, this initial study provides the rationale for considering this FDA-approved agent as an antifibrotic medication.
